A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic
M. Malimova, E.-H. Sidhom, A. Satyam, M. Dvela-Levitt, M. Melanson, B. T. Chamberlain, S. L. Alper, J. Santos, J. Gutierrez, A. Subramanian, E. Grinkevich, E. R. Bricio, C. Kim, A. Clark, A. Watts, , A. Greka
The paper identifies Fostamatinib as a potential repurposing drug for acute lung injury by reducing MUC1 protein levels in preclinical models.
bioRxiv · Jun 30, 2020Cell Biology